Novartis got a reprieve last week when the U.S. Patent and Trademark Office upheld a patent on its multiple sclerosis blockbuster Gilenya. Now, the Swiss pharma intends to extend that win to the legal system, hoping to block copycats from entering the U.S. until 2027.
The U.S. District Court for the District of New Jersey has restrained Dr. Reddy’s Laboratories from selling the generic version of British drugmaker Indivior’s Suboxone in the U.S., pending the outcome in a litigation over the patent of the opioid dependence treatment.
(Reuters) – A U.S. appeals court on Friday ruled invalid patents owned by Jazz Pharmaceuticals PLC covering its narcolepsy drug Xyrem, giving Amneal Pharmaceuticals Inc a boost in its effort to launch a generic version of the medicine. The U.S.
Only days after Dr. Reddy’s won a generic approval to Indivior’s top drug-the opioid addiction treatment Suboxone Film-a patent spat between the drugmakers is forcing the company to halt its copycat rollout. A U.S. court has issued a temporary restraining order against Dr. Reddy’s from making further sales after the Indian generics firm launched “at risk” on Friday.
Why should we encourage generics to challenge pharma patents? – IPWatchdog.com | Patents & Patent Law
What was the federal government thinking when Hatch-Waxman originally passed? Why would Congress incentivize generic manufacturers to challenge the patents of pharmaceutical companies? It is the same insidious thought process underlying Hatch-Waxman seen underlying the justification for post grant challenges.
A U.S. court has issued a temporary restraining order against Dr. Reddy’s Laboratories with respect to further sales and commercialisation of Buprenorphine and Naloxone sublingual film within the U.S. The order of the U.S.
Indian pharma major Dr Reddy’s Laboratories said today that a US District Court has issued a temporary restraining order on the sale and commercialisation of its generic Buprenorphine and Naloxone sublingual film in the American market. It is indicated for treatment of opioid dependence.
Shares of Dr. Reddy’s Laboratories (DRL) surged on Friday after the company said it planned to start selling in the U.S. a generic version of British drugmaker Indivior Plc’s Suboxone (buprenorphine and naloxone) sublingual film used in the treatment of opioid dependence. The Hyderabad-based firm said it had received approval from the U.S.
(Reuters) – India’s largest drugmaker Sun Pharmaceutical Industries Ltd said on Friday it expects its 2019 revenue to come in short of analysts’ expectations due to pricing pressure in its main market, the United States.
A divided federal appeals court on Wednesday upheld the validity of UCB BioPharma’s patent on epilepsy drug Vimpat, dashing the hopes of more than a dozen other drugmakers who sought to make generic versions before the patent expires in March 2022.
Early this year, Johnson & Johnson prostate cancer blockbuster Zytiga took an unexpected hit when a U.S. court stripped away a key patent, opening the prospect of generic launches later this year-a prospect J&J is working hard to avoid. But as of Wednesday, the $1.2 billion drug has copycat competition from another quarter.
Along with restructuring National Pharmaceutical Pricing Authority (NPPA), the Central government is also considering to give itself powers to exempt ‘orphan drugs’ and unbranded generic drugs from price control. ‘Orphan drugs’ are extremely expensive, as noted in the National Policy for Treatment of Rare Diseases (NPTRD), 2017.
Prime Minister Narendra Modi’s comment that doctors prescribe only branded medicines because of their nexus with pharmaceutical companies has not gone down well with the medical fraternity. The Indian Medical Association (IMA) has issued a statement saying the PM’s comment, made in London, harms the image of Indian doctors and will fracture the doctor-patient relationship.
Lawmakers are considering a bill to address what President Trump called a top priority in his State of the Union speech: lowering prescription drug prices. Critics say some drug companies who want to hold onto their exclusive sales of a brand-name drug – and their profits – are playing games to stave off generic competitors, leaving patients out in the cold.